ALXN1850 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 172 | 低ホスファターゼ症 | 1 |
172. 低ホスファターゼ症
臨床試験数 : 34 / 薬物数 : 19 - (DrugBank : 4) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 6
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04980248 (ClinicalTrials.gov) | July 22, 2021 | 23/7/2021 | Study of ALXN1850 in Participants With Hypophosphatasia (HPP) | A Phase 1, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1850 in Adults With Hypophosphatasia | Hypophosphatasia | Biological: ALXN1850 | Alexion Pharmaceuticals | NULL | Recruiting | 18 Years | N/A | All | 15 | Phase 1 | United States |